for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Ligand Says Partners Are Actively Progressing Two Omniab Antibody Discovery Programs For Potential Treatment Of Covid-19

April 6 (Reuters) - Ligand Pharmaceuticals Inc:

* LIGAND PHARMACEUTICALS - CO’S PARTNERS ARE ACTIVELY PROGRESSING TWO OMNIAB ANTIBODY DISCOVERY PROGRAMS FOR POTENTIAL TREATMENT OF COVID-19

* LIGAND PHARMACEUTICALS INC - ONE MULTINATIONAL BIG PHARMA PARTNER HAS INITIATED A PROGRAM USING OMNICHICKEN

* LIGAND PHARMACEUTICALS INC - ANOTHER PARTNER IS FOCUSED ON ANTIBODIES DERIVED FROM OMNIRAT

* LIGAND PHARMACEUTICALS INC - ESTIMATES THAT, AS OF MARCH 31, 2020, ITS CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $735 MILLION

* LIGAND PHARMACEUTICALS INC - ESTIMATES THAT, AS OF MARCH 31, 2020, OUTSTANDING CONVERTIBLE DEBT WAS APPROXIMATELY $516 MILLION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up